Open AccessIndiplon: the development of a novel therapy for the treatment of sleep onset and sleep maintenance insomnia
Author(s) -
Lankford A.,
AncoliIsrael S.
Publication year - 2007
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/j.1742-1241.2007.01322.x
Subject(s) - insomnia , medicine , hypnotic , zolpidem , benzodiazepine , sleep (system call) , sedative , sedation , sleep onset , clinical trial , psychiatry , sleep disorder , sedative/hypnotic , anesthesia , receptor , computer science , operating system
Summary Indiplon is a novel non‐benzodiazepine sedative‐hypnotic that modulates the GABA A receptor complex. It appears to be more selective for the α 1‐receptor subunit, associated with sedation, than other hypnotics. Two different formulations of indiplon have been developed: an immediate release (IR) version targeting sleep onset insomnia and a modified release (MR) version addressing sleep maintenance insomnia. Early results from clinical trials indicate that both formulations are well tolerated and effective at improving both objective and subjective measures of sleep. As of May 2006 indiplon‐IR has been provisionally approved for use in the US market and discussions are continuing with the FDA regarding the MR formulation.